ACADIA Pharmaceuticals to Announce Third Quarter 2012 Financial Results on November 5, 2012

ACADIA Pharmaceuticals to Announce Third Quarter 2012 Financial Results on
November 5, 2012
ACADIA to Host Conference Call and Webcast on Monday, November 5, 2012, at
5:00 p.m. Eastern Time
Business Wire
SAN DIEGO -- October 29, 2012
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today announced
that it will report its unaudited financial results for the third quarter
ended September 30, 2012 on Monday, November 5, 2012, after the U.S. financial
markets close. ACADIA's management will host a conference call and webcast on
Monday, November 5, 2012, at 5:00 p.m. Eastern Time to discuss ACADIA’s
financial results and development programs.
The conference call may be accessed by dialing 866-203-3436 for participants
in the U.S. or Canada and 617-213-8849 for international callers (reference
passcode 61271381). A telephone replay of the conference call may be accessed
through November 19, 2012 by dialing 888-286-8010 for callers in the U.S. or
Canada and 617-801-6888 for international callers (reference passcode
76643395). The conference call also will be webcast live on ACADIA’s website,
www.acadia-pharm.com, under the investors section and will be archived there
until November 19, 2012.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on innovative treatments that
address unmet medical needs in neurological and related central nervous system
disorders. ACADIA has a pipeline of product candidates led by pimavanserin,
which is in Phase III development as a potential first-in-class treatment for
Parkinson's disease psychosis. ACADIA also has clinical-stage programs for
chronic pain and glaucoma in collaboration with Allergan, Inc. and two
preclinical programs directed at Parkinson’s disease and other neurological
disorders. All of ACADIA’s product candidates are small molecules that emanate
from discoveries made using its proprietary drug discovery platform. ACADIA
maintains a website at www.acadia-pharm.com to which ACADIA regularly posts
copies of its press releases as well as additional information and through
which interested parties can subscribe to receive email alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature
are forward-looking statements. These statements include but are not limited
to statements related to the progress and timing of ACADIA’s drug discovery
and development programs, either alone or with a partner, including clinical
trials, and the benefits to be derived from ACADIA’s product candidates, in
each case including pimavanserin. These statements are only predictions based
on current information and expectations and involve a number of risks and
uncertainties. Actual events or results may differ materially from those
projected in any of such statements due to various factors, including the
risks and uncertainties inherent in drug discovery, development and
commercialization, and collaborations with others, and the fact that past
results of clinical trials may not be indicative of future trial results. For
a discussion of these and other factors, please refer to ACADIA’s annual
report on Form 10-K for the year ended December31, 2011 as well as ACADIA’s
subsequent filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this cautionary
statement and ACADIA undertakes no obligation to revise or update this press
release to reflect events or circumstances after the date hereof, except as
required by law.
Contact:
ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Executive Vice President,
Chief Financial Officer and Chief Business Officer
(858) 558-2871